Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

ts 2 years of age and older. Further studies are being performed to determine the long-term benefits and risks of Exjade.

Exjade is contraindicated in patients with hypersensitivity to deferasirox or to any other component of Exjade.

Cases of acute renal failure, some with a fatal outcome, have been reported following the post-marketing use of Exjade. Most of the fatalities occurred in patients with multiple comorbidities and who were in advanced stages of their hematologic disorders. There have also been reports of renal tubulopathy in patients treated with Exjade. Give particular attention to monitoring serum creatinine in patients who: are at increased risk of complications, have pre-existing renal conditions, are elderly, have comorbid conditions, or are receiving medicinal products that depress renal function.

Assess serum creatinine in duplicate before initiating therapy to establish a reliable pretreatment baseline, due to variations in measurements. Monitor serum creatinine monthly thereafter. In patients with additional renal risk factors (those who are at increased risk of complications, have pre-existing renal conditions, are elderly, have comorbid conditions, or are receiving medicinal products that depress renal function), monitor serum creatinine weekly during the first month after initiation or modification of therapy and monthly thereafter. Nonprogressive increases in serum creatinine have been noted in 38% of Exjade-treated patients, compared to 14% of deferoxamine-treated patients in Study 1 and 36% vs 22%, respectively in Study 3, and appear to be dose related. These increases were within the normal range in 94% of patients. Exjade dosages were adjusted when serum creatinine elevations were detected during the study.

Consider dose reduction, interruption, or discontinuation for elevations in serum creatinine. For adult patients, reduce daily dose of Exjade by 10
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... CENTER VALLEY, Pa. , Sept. 22, 2014 ... and delivering innovative solutions for medical and surgical ... has reached a deal with Munich ... distributor of Kick ® Navigation. This agreement ... maintain distribution for cross-disciplinary U.S. sales and all ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... N.J. , May 19 ... CardioTec, the first and only conference dedicated to addressing ... event, sponsored by Medical Product Outsourcing magazine, ... issues through a specialized agenda and extraordinary lineup of ...
... May 18 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... early termination of the waiting period under the Hart-Scott-Rodino ... previously announced sale of International Technidyne Corporation (ITC) to ...
Cached Medicine Technology:Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference 2Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference 3Thoratec Announces Early Termination of HSR Waiting Period for the Sale of ITC to Danaher Corporation 2
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... Diego CA (PRWEB) September 22, 2014 ... significantly expand its work to equip women around the ... on poverty. Through the Women Empowered (WE) Initiative ... will now join community-led groups to pool their savings, ... , “Women are the solution to ending poverty in ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global leader ... , WHAT: The 10th annual Customer Response Summit ... the connected consumer. Constant change in technology and ... and opportunities for customer experience executives. The Summit ... network and learn from fellow attendees, speakers and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... YORK, Oct. 8 "Fluoridation of drinking,water is scientifically ... initiative or program," says the Canadian Association of Physicians,for ... CAPE is Canada,s leading voice on environmental health issues., ... fluoridation of public,drinking water in several communities in Alberta, ...
... New interim guidance,that outlines how to become a ... U.S. Department of Health and Human Services., ... Safety Act),authorized the creation of PSOs to improve ... patient safety events. By providing both privilege,and confidentiality, ...
... appears to sustain insulin production in the newly diagnosed. ... have developed a vaccine that may change the way ... diagnosed with type 1 diabetes. , "By a very ... save [a person,s] own insulin secretion, which may be ...
... N.J., Oct. 8 Quest Diagnostics,Incorporated (NYSE: DGX ... services, announced today that its third-quarter,2008 results will be ... and that it will hold its quarterly conference call ... ET on that day., The public may access ...
... The following statement,of Matthew L. Myers was released today ... reports, R.J. Reynolds has announced plans to,test-market three new ... "fresh" and "mellow" flavors and have slick, colorful,packaging similar ... Orbs,these new products also carry the name of RJR,s ...
... HOLE, MA Osamu Shimomura, a senior scientist emeritus ... has been awarded the Nobel Prize in Chemistry for ... the most important tools in contemporary science and medicine ... Shimomura shares the prize, which was announced early today ...
Cached Medicine News:Health News:Physicians' Group Rejects Fluoridation 2Health News:HHS Issues Interim Guidance for Patient Safety Organizations 2Health News:New Vaccine May Help Type 1 Diabetics in Future 2Health News:New Vaccine May Help Type 1 Diabetics in Future 3Health News:Quest Diagnostics to Release Third Quarter 2008 Financial Results 2Health News:R.J. Reynolds' New Smokeless Products Will Appeal to Children and Show Need for FDA Regulation of Tobacco Products 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 3
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: